Please login to the form below

Not currently logged in
Email:
Password:

sHPT

This page shows the latest sHPT news and features for those working in and with pharma, biotech and healthcare.

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication

sHPT parathyroidism is a serious condition that affects a high proportion of CKD patients receiving dialysis. ... It is estimated that only around 25% of eligible patients take cinacalcet, mainly because most people with sHPT have a substantial number of

Latest news

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... Parsabiv (etelcalcetide) - a follow-up to Amgen's blockbuster Sensipar/Mimpara (cinacalcet) - has been given a green light to treat adult CKD patients on

  • Amgen wins European approval for Parsabiv Amgen wins European approval for Parsabiv

    European regulators have approved Amgen's Parsabiv (etelcalcetide), licensing it for secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ... The first new treatment to be approved for sHPT in more

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    Like its predecessor, the new calcimimetic drug - called Parsabiv ( etelcalcetide) - has been developed for the treatment of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD) who are on dialysis. ... Clinical trials also

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • PAN and DJM win prestigious Global Award

    of secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy, and it was for this indication that the award-winning work was produced.  .

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics